Rayaz Malik MBChB, PhD
Rayaz Malik MBChB, PhD
Principle Investigator
Professor of Medicine

Early Neuropathy group

Georgios Ponirakis BSc. MSc. MPhil.
Clinical Researcher in Medicine

Adnan Khan Cert. Ophth. PhD.
Post Doctoral Associate in Medicine

Ioannis Petropoulos BSc. MSc. PhD
Post Doctoral Associate in Medicine

Early Neuropathy Assessment (ENA) Group

The Early Neuropathy Assessment (ENA) is a group of clinician-scientists lead by Professor Rayaz Malik, based in the Research Division, Weill Cornell Medicine. The ENA group have pioneered the use of in vivo corneal confocal microscopy (CCM) as a rapid, non-invasive ophthalmic instrument to monitor damage and repair of corneal (sub-basal) nerves and act as a surrogate endpoint in diabetic and other peripheral neuropathies. The group have also developed ACCMetrics, a fully automated image analysis software allowing rapid and objective quantification of corneal nerve fibre morphology.


Our projects and studies

Dementia study

Principal Investigators:
Prof. Rayaz Malik (Professor of Medicine & Senior Consultant, WCM-Q & HMC)
Dr. Hanadi Al Hamad (Chairman of Geriatric Dept. & Senior Consultant, WCM-Q & HMC)

Mr. Georgios Ponirakis (Clinical Researcher)
Dr. Adnan Khan (Post Doctoral Associate in Medicine)
Dr. Marwan Ramadan (Consultant)
Dr. Shafi Khan (Consultant)
Dr. Essa AlSulaiti (Consultant)
Ms. Priya Vitthal Gawhale (Nurse)
Ms. Rhia Tosino (Nurse)
Dr. Susan Osman (Consultant)
Dr. Navas Nadukkandiyil (Consultant)
Dr. Maryam Alobaidi (Consultant)
Dr. Ioannis Petropoulos (Post Doctoral Associate in Medicine)
Prof. Ashfaq Shuaib (Director of Neuroscience Institute)

Early identification of dementia is important to ensure patients are offered treatment early in order to achieve a better quality of life and more independence. The objectives of this study are as follows:

    To prospectively use CCM in patients attending the memory clinic to:
  1. Study its clinical potential as a dementia biomarker.
  2. Characterise corneal nerve/endothelial changes seen in patients with cognitive impairment and/or dementia.
  3. Identify corneal/endothelial changes that will assist in identifying or differentiating patients with different types of dementia (e.g. Alzheimer's versus Vascular) and different severity (mild versus moderate versus severe) of cognitive impairment and/or dementia.

Last modified on Tuesday, 29-Nov-2016 13:30:57 +03